These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 28110415)

  • 1. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
    Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F
    Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
    Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
    Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?
    Wu PF; Lin YT; Wang FD; Yang TC; Fung CP
    Infection; 2018 Jun; 46(3):365-373. PubMed ID: 29556979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Pseudomonas aeruginosa bacteraemia in a tertiary hospital: Mortality and prognostic factors.
    Callejas-Díaz A; Fernández-Pérez C; Ramos-Martínez A; Múñez-Rubio E; Sánchez-Romero I; Vargas Núñez JA
    Med Clin (Barc); 2019 Feb; 152(3):83-89. PubMed ID: 29885868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia.
    Cheong HS; Kang CI; Wi YM; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
    Eur J Clin Microbiol Infect Dis; 2008 Dec; 27(12):1219-25. PubMed ID: 18575908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies.
    Hu Y; Li L; Li W; Xu H; He P; Yan X; Dai H
    Int J Antimicrob Agents; 2013 Dec; 42(6):492-6. PubMed ID: 24139926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.
    Bowers DR; Liew YX; Lye DC; Kwa AL; Hsu LY; Tam VH
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1270-4. PubMed ID: 23263001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
    Chamot E; Boffi El Amari E; Rohner P; Van Delden C
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2756-64. PubMed ID: 12936970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment failure due to induction of ciprofloxacin resistance during combination therapy with colistin and ciprofloxacin in multidrug-resistant Pseudomonas aeruginosa bacteraemia.
    Kim J; Kang CI; Baek JY; Cho SY; Kim SH; Ko KS; Chung DR; Peck KR; Song JH
    Int J Antimicrob Agents; 2014 Apr; 43(4):391-3. PubMed ID: 24637223
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
    Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
    J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.
    Vardakas KZ; Tansarli GS; Bliziotis IA; Falagas ME
    Int J Antimicrob Agents; 2013 Apr; 41(4):301-10. PubMed ID: 23410791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudomonas aeruginosa bloodstream infections: how should we treat them?
    van Delden C
    Int J Antimicrob Agents; 2007 Nov; 30 Suppl 1():S71-5. PubMed ID: 17698326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort.
    Peña C; Suarez C; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez F; Tubau F; Oliver A; Martínez-Martínez L;
    Clin Infect Dis; 2013 Jul; 57(2):208-16. PubMed ID: 23580739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel β-lactam-β-lactamase inhibitors as monotherapy versus combination for the treatment of drug-resistant Pseudomonas aeruginosa infections: A multicenter cohort study.
    Almangour TA; Ghonem L; Alassiri D; Aljurbua A; Al Musawa M; Alharbi A; Almuhisen S; Alghaith J; Damfu N; Aljefri D; Alfahad W; Alrasheed M; Khormi Y; Almohaizeie A
    J Infect Chemother; 2024 Oct; 30(10):1008-1014. PubMed ID: 38537776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.
    Suárez C; Peña C; Gavaldà L; Tubau F; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e73-8. PubMed ID: 20223693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.
    Kim YJ; Jun YH; Kim YR; Park KG; Park YJ; Kang JY; Kim SI
    BMC Infect Dis; 2014 Mar; 14():161. PubMed ID: 24655422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas aeruginosa bacteraemia. Is pancreatobiliary disease a risk factor?
    Chen SC; Lawrence RH; Byth K; Sorrell TC
    Med J Aust; 1993 Nov; 159(9):592-7. PubMed ID: 8232033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy.
    Schechner V; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Finkelstein R; Lachish T; Wiener-Well Y; Alon D; Chowers M; Bardenstein R; Zimhony O; Paz A; Potasman I; Giladi M; Schwaber MJ; Klarfeld-Lidji S; Hochman M; Marchaim D; Carmeli Y
    Diagn Microbiol Infect Dis; 2011 Sep; 71(1):38-45. PubMed ID: 21763093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.